PURPOSE: To compare the efficacy and safety of same-day @entity4936 photodynamic therapy (PDT) and intravitreal ranibizumab @entity18274 treatment versus ranibizumab monotherapy in neovascular age-related @entity1020 . DESIGN: Prospective, multicenter, double-masked, randomized, active-controlled trial. @entity1 : We included 255 @entity1 with all types of active subfoveal @entity1940 . METHODS: @entity1 were randomized 1:1 to as-needed (pro re nata; PRN) @entity18274 (standard-fluence @entity4936 6 mg/m(2) PDT and ranibizumab 0.5 mg) or PRN ranibizumab monotherapy (sham infusion [5% dextrose] PDT and ranibizumab 0.5 mg). @entity1 received 3 consecutive monthly injections followed by PRN retreatments based on protocol-specific retreatment criteria. MAIN OUTCOME MEASURES: Mean change in best-corrected visual acuity (BCVA) from baseline to month 12, and the proportion of @entity1 with treatment-free interval >= 3 months at any timepoint after month 2. RESULTS: The mean change in BCVA at month 12 was +2.5 and +4.4 letters in the @entity18274 and monotherapy groups, respectively (P = 0.0048; difference: -1.9 letters [95% confidence interval, -5.76 to 1.86], for having achieved noninferiority with a margin of 7 letters). The proportion of @entity1 with a treatment-free interval of >= 3 months at any timepoint after month 2 was high, but did not show a clinically relevant difference between the treatment groups. Secondary efficacy endpoints included the mean number of ranibizumab retreatments after month 2 (1.9 and 2.2 with @entity18274 and monotherapy, respectively [P = 0.1373]). The time to first ranibizumab retreatment after month 2 was delayed by 34 days (about 1 monthly visit) with @entity18274 (month 6) versus monotherapy (month 5). At month 12, mean    standard error central retinal thickness decreased by 115.3  9.04  m in the @entity18274 group and 107.7  11.02  m in the monotherapy group. The mean number of @entity4936 /sham PDT treatments was comparable in the 2 groups ( @entity18274 , 1.7; monotherapy, 1.9). The safety profiles of the 2 groups were comparable, with a low incidence of ocular serious adverse events. CONCLUSIONS: The @entity18274 PRN treatment regimen with @entity4936 PDT and ranibizumab was effective in achieving BCVA gain comparable with ranibizumab monotherapy; however, the study did not show benefits with respect to reducing the number of ranibizumab retreatment over 12 months. The @entity18274 therapy was well tolerated.

@entity4936 plus ranibizumab for XXXX in age-related @entity1020 : twelve-month MONT BLANC study results.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PARTICIPANTS'] @entity4936 :: ('MESH:C098350', 'Chemical') :: ['verteporfin'] @entity1940 :: ('MESH:D020256', 'Disease') :: ['choroidal neovascularization'] @entity18274 :: ('MESH:D009100', 'Disease') :: ['combination'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['macular degeneration']
@entity1940 :: (MESH:D020256,Disease) :: ['choroidal neovascularization']
